Comment on “Clinical and endoscopic features of checkpoint inhibitor-induced colitis and their association with selective immunosuppressive therapy use”

Clicks: 16
ID: 333294
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #83 of 101 articles by views in inflammatory bowel diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To the Editors, Naber et al.1 report a well-characterized 2-center cohort of patients with histologically confirmed immune checkpoint inhibitor (ICI) colitis in which every endoscopy was rescored from the original images by IBD specialists, who were the first to examine endoscopic predictors of selective immunosuppressive therapy (SIT) separately by ICI class.1 We would value knowing the thoughts of the authors Naber et al. on 3 questions. The SIT diagnosis was used as a treatment decision as much as a disease state and was reached along very different timelines in the 2 groups, with a median of 7 days under anti-cytotoxic T-lymphocyte-associated protein 4 (aCTLA-4)–based therapy and 60 days under anti-programmed cell death protein 1/programmed death-ligand 1 (aPD-[L]1) therapy. The use of SIT at any point during follow-up therefore combines primary steroid refractory colitis with later steroid dependent or relapsing disease, and baseline endoscopy might not be expected to predict both equally. Since earlier SIT has been associated with shorter hospitalization and fewer steroid-tapering failures,2 thresholds for escalation may also have shifted across the 2014 to 2024 study period. Would analyzing the time to SIT with death as a competing risk and separating primary refractoriness from later escalation recover a signal that a binary endpoint may absorb?
Reference Key
openalex_W7223144416 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hui Luo, Jingyuan Li, Ting Ye
Are you one of these authors? Claim your profile
Journal inflammatory bowel diseases
Year 2026
DOI
10.1093/ibd/izag205
URL
https://doi.org/10.1093/ibd/izag205
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.